Key words: etanercept, ankylosing spondylitis, psoriatic arthritis, safety, pharmacoeconomy

1Rheumatology Department of Lucania, San Carlo Hospital of Potenza, Potenza; 2Department of Health Sciences, University of Molise, Campobasso; 3Rheumatology Unit, 2nd Division of Medicine, Prato Hospital, Prato; 4Academic Rheumatology Unit, Department of Health Science, University of Molise, Campobasso, Italy; 5UOC Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milano; 6Chair of Rheumatology, Department of Medical Sciences, University of Cagliari, Cagliari; 7Rheumatology Unit, Arcispedale S. Maria Nuova, Reggio Emilia; 8Academic Rheumatology Unit, University of Naples Federico II, Napoli; 9Department of Internal Medicine and Medical Specialties, Division of Rheumatology, “Sapienza” University of Rome Roma, Italy. Salvatore D’Angelo, MD Carlo Palazzi, MD Fabrizio Cantini, MD Ennio Lubrano, MD Antonio Marchesoni, MD Alessandro Mathieu, MD Carlo Salvarani, MD Raffaele Scarpa, MD Antonio Spadaro, MD Ignazio Olivieri, MD Please address correspondence to: Dr Ignazio Olivieri, Rheumatology Department of Lucania, San Carlo Hospital, Contrada Macchia Romana, 85100 Potenza, Italy. E-mail: [email protected] Received on April 16, 2011; accepted in revised form on July 11, 2011. Clin Exp Rheumatol 2011; 29: 865-870. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2011.